{"title":"Cross-Reactivity of GeneXpert MTB/RIF Probe C with <i>Nocardia</i> Species as a Suggestive Ancillary Indicator.","authors":"Yanyan Fan, Rongrong Song, Jingyi Feng, Jiankang Zhao","doi":"10.2147/IDR.S633640","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The slow-growing, fastidious nature of <i>Nocardia</i> species makes rapid molecular tools essential for diagnosis. Although the GeneXpert MTB/RIF assay targets <i>Mycobacterium tuberculosis</i> (MTB), the cross-reactivity of its Probe C with <i>Nocardia</i> has not previously been characterized.</p><p><strong>Methods: </strong>We retrospectively analyzed 14,141 non-duplicate clinical samples from February 2020 to June 2023. Probe C reactivity was first assessed against <i>Nocardia</i> culture results. To investigate the molecular basis, we subsequently compared the <i>rpoB</i> target region of Probe C with the genomes of 1082 <i>Nocardia</i> strains from the NCBI database.</p><p><strong>Results: </strong>Probe C showed species-specific reactivity, failing to detect many clinically prevalent species. Among culture-positive <i>Nocardia</i> isolates, Probe C detected 10 of 17 <i>N. cyriacigeorgica</i> (Ct range: 32.8-39.2), 1 of 2 <i>N. asiatica</i> (Ct: 39), and 2 of 8 <i>N. abscessus</i> (Ct range: 30.5-38.7). Notably, the most frequently isolated species, <i>N. farcinica</i> (59 isolates), showed no Probe C reactivity. The overall sensitivity of Probe C among all culture-confirmed nocardiosis cases was only 13.4% (13/97); even among the subset of cross-reacting species, it reached only 48.1% (13/27), highlighting its inadequacy as a standalone diagnostic test. In the full MTB-negative cohort, the Probe C-positive rate was just 0.27% (38/14,141), with 25 of those 38 signals lacking culture confirmation. Genome alignment confirmed 100% identity between the <i>rpoB</i> sequences of reactive <i>Nocardia</i> strains and the Probe C target region.</p><p><strong>Conclusion: </strong>Probe C is the first MTB-targeted tool demonstrated to cross-react with <i>Nocardia</i> via <i>rpoB</i> homology, with genomic evidence ruling out other genetic sources. However, given the low overall sensitivity of Probe C among all culture-confirmed nocardiosis cases, the restricted species spectrum, and the lack of molecular confirmation for most positive signals at high Ct values, an isolated Probe C-positive result in an MTB-negative sample should be regarded as a suggestive, non-diagnostic ancillary hint that warrants <i>Nocardia</i>-specific confirmatory testing rather than as a diagnostic finding.</p>","PeriodicalId":13577,"journal":{"name":"Infection and Drug Resistance","volume":"19 ","pages":"633640"},"PeriodicalIF":3.2000,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590008/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection and Drug Resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IDR.S633640","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The slow-growing, fastidious nature of Nocardia species makes rapid molecular tools essential for diagnosis. Although the GeneXpert MTB/RIF assay targets Mycobacterium tuberculosis (MTB), the cross-reactivity of its Probe C with Nocardia has not previously been characterized.
Methods: We retrospectively analyzed 14,141 non-duplicate clinical samples from February 2020 to June 2023. Probe C reactivity was first assessed against Nocardia culture results. To investigate the molecular basis, we subsequently compared the rpoB target region of Probe C with the genomes of 1082 Nocardia strains from the NCBI database.
Results: Probe C showed species-specific reactivity, failing to detect many clinically prevalent species. Among culture-positive Nocardia isolates, Probe C detected 10 of 17 N. cyriacigeorgica (Ct range: 32.8-39.2), 1 of 2 N. asiatica (Ct: 39), and 2 of 8 N. abscessus (Ct range: 30.5-38.7). Notably, the most frequently isolated species, N. farcinica (59 isolates), showed no Probe C reactivity. The overall sensitivity of Probe C among all culture-confirmed nocardiosis cases was only 13.4% (13/97); even among the subset of cross-reacting species, it reached only 48.1% (13/27), highlighting its inadequacy as a standalone diagnostic test. In the full MTB-negative cohort, the Probe C-positive rate was just 0.27% (38/14,141), with 25 of those 38 signals lacking culture confirmation. Genome alignment confirmed 100% identity between the rpoB sequences of reactive Nocardia strains and the Probe C target region.
Conclusion: Probe C is the first MTB-targeted tool demonstrated to cross-react with Nocardia via rpoB homology, with genomic evidence ruling out other genetic sources. However, given the low overall sensitivity of Probe C among all culture-confirmed nocardiosis cases, the restricted species spectrum, and the lack of molecular confirmation for most positive signals at high Ct values, an isolated Probe C-positive result in an MTB-negative sample should be regarded as a suggestive, non-diagnostic ancillary hint that warrants Nocardia-specific confirmatory testing rather than as a diagnostic finding.
期刊介绍:
About Journal
Editors
Peer Reviewers
Articles
Article Publishing Charges
Aims and Scope
Call For Papers
ISSN: 1178-6973
Editor-in-Chief: Professor Suresh Antony
An international, peer-reviewed, open access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventative strategies to minimize the development and spread of resistance.